Understanding how price, revenue and profit margins can be maximised is key to commercial success.
The differences between cell and gene therapies and other types of therapies mean developing robust pricing and reimbursement strategies demands additional considerations to those of conventional pharmaceuticals. These considerations also need to be addressed earlier in development given the higher commercial risk cell and gene therapies present.
The health economics and market access team provides health economics, pricing, reimbursement and market access expertise to accelerate and maximise cell therapy uptake across global healthcare market.
Together, with our dedicated team, we can help develop your health-economic arguments and models, your value story and pricing and reimbursement strategy to accelerate and maximise your therapy’s uptake and revenue potential.
We can help you optimise the use of your resources – selecting the right target population and therapeutic position before you start clinical development so that there is enough room for innovation to accommodate a high cost therapy.
We’ll work with you on your product design, and target product profile, to help your therapy become a commercial success.
We can help with planning your evidence generation so that it meets the requirements of key market access stakeholders.
Given the high manufacturing and delivery costs, we help define product performance and manufacturing cost thresholds for commercial viability so that your clinical and manufacturing strategies are informed accordingly.
We’ll help you work out a clear pathway for reimbursement and adoption of your therapy across major global healthcare markets.
For typical assessments undertaken by our market access team, please view the following document: The Cell and Gene therapy Catapult approach to pricing and reimbursement strategy development.
We provide health economic and market access support along all stages of a cell and gene therapy’s route to market with an emphasis on addressing the unique challenges that ATMPs present including:
- shaping value proposition and evidence generation plans in order to secure commercially viable profit margins (by defining product performance and manufacturing cost thresholds)
- addressing key ATMP challenges at launch including data uncertainty, affordability and NHS readiness for therapy adoption
For examples of how we help optimise adoption potential in the pre-clinical and pre-pivotal stages of development, please view the following document: Early Stage Commercial Risk Mitigation
Our health economists and market access professionals are the only team in Europe that focus exclusively on cell and gene therapies, which has helped us to understand and develop strategies that address the unique barriers to reimbursement you would face.
Furthermore through the Cell and Gene Therapy Catapult’s coordinating role of the Advanced Therapy Treatment Centres in the UK, we have first-hand experience on NHS preparedness matters for therapy adoption and how this differs across different types of ATMPs.
In addition, we are directly involved in a variety of environmental shaping initiatives that help pave the way for enabling timely adoption of cell and gene therapies. We actively identify industry-wide bottlenecks to reimbursement and adoption, and work together with HTA bodies, healthcare systems and their commissioners, policy makers and industry associations across European and North American countries to ensure that assessments, policies, processes and infrastructure can accommodate the specific needs of ATMPs.
In response to the lack of sufficient information on market access processes for cell and gene therapies in the major European markets, we compiled a set of reimbursement roadmaps and in-depth presentations covering the Big5 EU: France, Germany, Italy, Spain and the UK.
For additional examples of our health economics and market access work, please see:
- Exploring the per-patient cost of long term value based agreements (VBAs)
- Exploring the cost of implementing long term VBAs within the NHS (1)
- Exploring the cost of implementing long term VBAs within the NHS (2)
- To what extent can the European Society for Blood and Marrow Transplantation (EBMT) registry enable outcomes-based reimbursement in oncology in the UK?
- To what extent can the Systemic Anti-Cancer Therapy (SACT) database enable outcomes-based reimbursement in oncology in England?
- The appropriateness of the NHR for facilitating performance-based reimbursement in thalassaemia – current state and future perspectives
For our peer reviewed-publications by our health economics and market access team, please see:
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate, Journal of Market Access & Health Policy 2019, VOL. 7.1, 1635842
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s. J Mark Access Health Policy 2018, VOL. 6, 1500419
Contact us to find out more about our health economics and market access capabilities.